The role of prostacyclin in atherosclerosis

Pharmacological Research Communications

Volumn 20, Issue SUPPL. 3, 1988, Pages 71-83

  Sinzinger, H ^a  

^a ERICH SCHMID INSTITUTE OF MATERIALS SCIENCE   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ILOPROST; PROSTACYCLIN; PROSTAGLANDIN;

ARTERIOSCLEROSIS; HUMAN; NONHUMAN; PERIPHERAL VASCULAR DISEASE; REVIEW; SHORT SURVEY; THROMBOCYTE;

ANIMAL; ARTERIOSCLEROSIS; EPOPROSTENOL; HUMAN; PLATELET AGGREGATION; PLATELET-DERIVED GROWTH FACTOR;

EID: 0023772187     PISSN: 00316989     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0031-6989(88)80107-3     Document Type: Article

References (50)

1. Accelerated prostacyclin degradation in thrombotic thrombocytopenic purpura
2. Serotonin receptor mediated stimulation of bovine smooth muscle cell prostacyclin synthesis and its modulation by platelet derived growth factor
3. The generation of prostacyclin by arteries and by the coronary vascular bed is reduced in experimental atherosclerosis in rabbit
4. Prostaglandine in Pathogenese und Therapie der peripheren arteriellen Verschlußkrankheit (PVK)
5. Estimated rate of prostacyclin secretion into the circulation of normal man
6. The effect of prostaglandins PGE1 and PGE2 on cholesterol efflux from human monocyte-derived macrophages
7. Modulation of human platelet adenylate cyclase by prostacyclin (PGX)
8. Prostacyclin modulates cholesteryl ester hydrolytic activity by his effect on cyclic adenosine monophosphate in rabbit aortic smooth muscle cells
9. Defekte im Prostaglandinsystem. II. Familiärer Plättchen-Prostacyclin-Rezeptor-Defekt (Defekt Wien-Hietzing) — pathogenetische Bedeutung für (frühzeitige) Entstehung der Atherosklerose?
10. Prostacyclin synthesis by proliferative smooth muscle cells
11. Recurrence of hemolytic uremic syndrome triggered by cyclosporine after renal transplantation
12. 2) in uraemia and haemodialysis
13. Parathyroid hormone does not inhibit platelet aggregation
14. Localisation and stimulation of prostacyclin production in vascular cells
15. 2
16. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation
17. 1 on DNA-synthetis in vascular smooth muscle cells
18. Prostacyclin synthesis stimulating plasma factor in patients with different stages of hepatic coma
19. 1alpha levels in plasma of patients with colonic cancer
20. Haemolytic-uraemic syndrome : deficiency of plasma factor(s) regulating prostacyclin activity
21. Plasma factor modulating prostaglandin synthesis : a possible role in uremic bleeding and in thrombotic-thrombocytopenic purpura
22. A platelet-dependent serum factor that stimulates the proliferation of arterial smooth muscle cells in vitro
23. Selective binding site for (3H) prostacyclin on platelets
24. Decreased vascular prostacyclin in juvenile onset diabetes
25. Prostacyclin generation in atherosclerotic arteries
26. The effect of ballooning on minipig aortic prostacyclin formation — a time course
27. 2)-formation?
28. 2) regulate human arterial intima smooth muscle cell proliferation in early atherogenesis?
29. Sensitivity of platelets to prostaglandins in coronary heart disease and angina pectoris
30. 2 during long-term intraarterial prostacyclin infusion in patients with peripheral vascular disease — a rebound phenomenon?
31. Is the platelet derived growth factor (PDGF) a main regulator in atherosclerosis?
32. Passive smoking severely decreases platelet sensitivity to antiaggregatory prostaglandins
33. Epoprostenol (prostacyclin) decreases platelet deposition on vascular prosthetic grafts
34. Epoprostenol and platelet deposition in atherosclerosis
35. Rebound platelet activation during continuous epoprostenol infusion
36. Extremely low-dose aspirin (1 mg per day) renders human platelets more sensitive to antiaggregation prostaglandins
37. Defekte im Prostaglandinsystem.-I. Familiärer, vollständinger Plasmafaktormangel
38. Defekte im Prostaglandinsystem. IV. Angeborener, nichtfamiliärer Plasmafaktormangel
39. Defekte im Prostaglandinsystem. V. Vererbte (?) Störung des Prostazyklinabbaus im Plasma (Defekt Wien-Döbling)
40. Beschleunigter Abbau von Prostazyklin im diabetischen Plasma — ein weiterer Faktor der Störung des Hämostsegleichgewichtes?
41. Klinische Bedeutung des Plasmafaktordefektes : Ist eine präventive Therapie empfehlenswert?
42. Imaging and monitoring of human atherosclerotic lesions with radiolabelled platelets
43. Prostacyclin synthesis stimulating plasma factor in patients with primary hyperlipoproteinemia — effect of dietary and drug treatment
44. Prostacyclin synthesis stimulating plasma factor in coronary heart disease
45. 2 infusion occurs at the receptor level
46. 2 is important for atherosclerosis
47. 1 (via different mechanisms ?) on activation of human vascular smooth muscle cells
48. Successful therapy of arteriosclerosis obliterans with prostacyclin
49. Suppression of principal atherosclerotic mechanisms by prostacyclins and other eicosanoids
50. 2 on smooth muscle cell proliferation